Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(3)
•••
Comment by longterm56on Jun 08, 2020 10:48pm
112 Views
Post# 31127165

RE:RE:RE:RE:RE:RE:RE:RE:Wino

RE:RE:RE:RE:RE:RE:RE:RE:Wino
Victura wrote: Out of curiosity long term (as a eager student of investing looking to learn), what valuation do you have for this company and what is it based around?  I don't ask to be challenging but simply to understand since it's such a unique stock.

  • $6 US for existing products (Egrifta & Trogarzo) as sales increase in Europe and in US (due to new CEO's efforts) ... this may take another 1-2 years 
  • At least $11 US when investors are convinced that Egrifta will be approved for NAFLD/NASH for HIV patients... based on the fact that the market was willing to pay that much for TH just based on potential Trogarzo sales 2 years ago. But this also may take another 1-2 years.
  • No value for cancer pipe line yet ... but this may change in 1-2 years. 
Either way, it's a great buy-in price right now ... but patience is required ... 

  -LT




Bullboard Posts
Dealroom for high-potential pre-IPO opportunities